<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="other" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Annals of the Russian academy of medical sciences</journal-id><journal-title-group><journal-title xml:lang="en">Annals of the Russian academy of medical sciences</journal-title><trans-title-group xml:lang="ru"><trans-title>Вестник Российской академии медицинских наук</trans-title></trans-title-group></journal-title-group><issn publication-format="print">0869-6047</issn><issn publication-format="electronic">2414-3545</issn><publisher><publisher-name xml:lang="en">"Paediatrician" Publishers LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">65</article-id><article-id pub-id-type="doi">10.15690/vramn.v70i1.1225</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>РATHOPHYSIOLOGY: CURRENT ISSUES</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>АКТУАЛЬНЫЕ ВОПРОСЫ ПАТОФИЗИОЛОГИИ</subject></subj-group><subj-group subj-group-type="article-type"><subject></subject></subj-group></article-categories><title-group><article-title xml:lang="en">THE COMPARATIVE ANALYSIS OF AMYLOIDOSIS VARIOUS MODELS</article-title><trans-title-group xml:lang="ru"><trans-title>СРАВНИТЕЛЬНЫЙ АНАЛИЗ РАЗЛИЧНЫХ МОДЕЛЕЙ АМИЛОИДОЗА</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Kozlov</surname><given-names>V. A.</given-names></name><name xml:lang="ru"><surname>Козлов</surname><given-names>В. А.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="ru"><p>доктор биологических наук, кандидат медицинских наук, профессор кафедры фармакологии, клинической фармакологии и биохимии Чувашского государственного университета им. И.Н. Ульянова Адрес: 428015, Чебоксары, Московский пр-т, д. 45, тел.: +7 (8352) 45-26-73</p></bio><email>pooh12@yandex.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Sapozhnikov</surname><given-names>S. P.</given-names></name><name xml:lang="ru"><surname>Сапожников</surname><given-names>С. П.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="ru"><p>доктор медицинских наук, заведующий кафедрой медицинской биологии с курсом микробиологии и вирусологии Чувашского государственного университета им. И.Н. Ульянова  Адрес: 428015, Чебоксары, Московский пр-т, д. 45, тел.: +7 (8352) 45-26-73</p></bio><email>pooh12@yandex.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Sheptukhina</surname><given-names>A. I.</given-names></name><name xml:lang="ru"><surname>Шептухина</surname><given-names>А. И.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="ru"><p>студентка 5-го курса медицинского факультета Чувашского государственного университета им. И.Н. Ульянова  Адрес: 428015, Чебоксары, Московский проспект, д. 45, тел.: +7 (8352) 45-26-73</p></bio><email>pooh12@yandex.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Golenkov</surname><given-names>A. V.</given-names></name><name xml:lang="ru"><surname>Голенков</surname><given-names>А. В.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="ru"><p>доктор медицинских наук, профессор, заведующий кафедрой психиатрии, медицинской психологии и неврологии Чувашского государственного университета им. И.Н. Ульянова  Адрес: 428015, Чебоксары, Московский пр-т, д. 45, тел.: +7 (8352) 45-26-73</p></bio><email>pooh12@yandex.ru</email><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">I.N. Ul’yanov Chuvash State University, Cheboksary, Russian Federation</institution></aff><aff><institution xml:lang="ru">Чувашский государственный университет им. И.Н. Ульянова, Чебоксары, Российская Федерация</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2015-01-28" publication-format="electronic"><day>28</day><month>01</month><year>2015</year></pub-date><volume>70</volume><issue>1</issue><issue-title xml:lang="en">Vestnik Rossiiskoi akademii medetsinskikh nauk / Annals of the Russian academy of medical sciences</issue-title><issue-title xml:lang="ru">Вестник Российской академии медицинских наук</issue-title><fpage>5</fpage><lpage>11</lpage><history><date date-type="received" iso-8601-date="2015-08-07"><day>07</day><month>08</month><year>2015</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2015, "Paediatrician" Publishers LLC</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2015, Издательство "Педиатръ"</copyright-statement><copyright-year>2015</copyright-year><copyright-holder xml:lang="en">"Paediatrician" Publishers LLC</copyright-holder><copyright-holder xml:lang="ru">Издательство "Педиатръ"</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/" start_date="2016-01-11"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://vestnikramn.spr-journal.ru/jour/about/submissions</ali:license_ref></license></permissions><self-uri xlink:href="https://vestnikramn.spr-journal.ru/jour/article/view/65">https://vestnikramn.spr-journal.ru/jour/article/view/65</self-uri><abstract xml:lang="en"><p><italic>Considered natural and experimental amyloidosis models in the existing theories context and known amyloidogenesis mechanisms. Available clinical and experimental observations indicate that the opinion of a fatal incurable amyloidosis wrong. It is shown that there is a significant amount of experimental easily replicable amyloidosis models, which may be used for practicing the treatment methods of this pathology. We offer an amyloidosis models classification: natural (animal models with generic amyloidosis), cell clones, artificial (infectious, protein, etc.). Based on the analysis of amyloidosis existing models concluded — none of the accepted in the scientific the theories community for amyloid building does not combine or explains all known facts about the amyloidogenesismechanisms. It is assumed that there is a proteins group, the beta-sheet structure, which are potentially capable of amyloid conformation building. It is assumed that beta-sheets of these proteins have similar amino acid composition. The condition for the amyloid building conformation is getting too much protein in sufficient quantities in an uncharacteristic place where the ionic strength of the tissue fluid is such that it promotes the amyloid building conformation. It is assumed that an unfortunate amount of ionic strength environment amyloid protein is provided by polysaccharides, tubulins proteins and ionized silicon.</italic></p><p> </p></abstract><trans-abstract xml:lang="ru"><p><italic>Рассмотрены естественные и экспериментальные модели амилоидоза в контексте существующих теорий и известных механизмов амилоидогенеза. Имеющиеся клинические и экспериментальные наблюдения свидетельствуют, что мнение о фатальной неизлечимости амилоидоза неверно. Показано, что существует значительное количество экспериментальных достаточно легко воспроизводимых моделей амилоидоза, которые могут быть использованы для отработки методов лечения этой патологии. Предложена классификация моделей амилоидоза: естественные (животные модели с генуинным амилоидозом), клеточные клоны, артифициальные (инфекционные, белковые, прочие). На основании анализа существующих моделей амилоидоза сделан вывод о том, что ни одна из принятых в научном сообществе теорий образования амилоида не объединяет и не объясняет все известные факты о механизмахамилоидогенеза. Предположено, что существует группа белков, структура β-листа которых потенциально способна к образованию амилоиднойконформации, и что β-листы таких белков имеют близкий аминокислотный состав. Условие образования амилоидной конформации — это попадание такого белка в достаточном количестве в несвойственное ему место, где ионная сила тканевой жидкости такова, что способствует образованию амилоидной конформации. По-видимому, неблагоприятная величина ионной силы среды окружения амилоидного белка обусловлена влиянием полисахаридов, тубулиновых белков и ионизированного кремния.</italic></p><p> </p></trans-abstract><kwd-group xml:lang="en"><kwd>amyloid</kwd><kwd>amyloidosismodels: natural (animal, cellular), artificial</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>амилоид</kwd><kwd>модели амилоидоза: естественные (животные, клеточные), артифициальные</kwd></kwd-group><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>1. Kozlovskaya L.V., Rameev V.V., Sarkisova I.A. Amyloidosis in the elderly. Klinicheskaya meditsina: Nauchno-prakticheskii zhurnal = Clinical Medicine: Scientific and practical journal. 2005; 83 (6): 12–20.</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>2. Chiu K., So K.-F., Chuen-Chung Chang R. Progressive Neurode-generation of Retina in Alzheimer’s disease – Are β-Amyloid Peptide and Tau New Pathological Factors in Glaucoma? Glaucoma. Basic and Clinical Aspects. 2013. Rumelt Sh. (ed.). http://www. intechopen.com/books/glaucoma-basic-and-clinical-aspects/ progressive-neurodegeneration-of-retina-in-alzheimer-s-disease-are-amyloid-peptide-and-tau-new-patho (available: 27.01.2015)</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>3. Kitazawa M., Green K.N., Caccamo A., La Ferla F.M. Genetically augmenting Abeta42 levels in skeletal muscle exacerbates inclusion body myositis-like pathology and motor deﬁcits in transgenic mice. Am. J. Pathol. 2006; 168 (6): 1986–1997.</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>4. Vattemi G., Nogalska A., King Engel W., D’Agostino C., Checler F., Askanas V. Amyloid-beta 42 is preferentially accumulated in muscle ﬁbers of patients with sporadic inclusion-body myositis. Acta Neuropathol. 2009; 117 (5): 569–574.</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>5. Gomperts S.N., Rentz D.M., Moran E., Becker J.A., Locascio J.J., Klunk W.E., Mathis C.A., Elmaleh D.R., Shoup T., Fischman A.J., Hyman B.T., Growdon J.H., Johnson K.A. Imaging amyloid deposition in Lewy body diseases. Neurology. 2008; 71 (12): 903–910.</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>6. Irvine G.B., El-Agnaf O.M., Shankar G.M., Walsh D.M. Protein aggregation in the brain: the molecular basis for Alzheimer’s and Parkinson’s diseases. Mol. Med. 200 8; 14: 451–464.</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>7. Head E., Lott I.T. Down syndrome and beta-amyloid deposition. Curr. Opin. Neurol. 2004; 17 (2): 95–100.</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>8. Luheshi L.V., Dobson C.M. Bridging the gap: from protein misfolding to protein misfolding diseases. FEBS Lett. 2009; 583: 2581–2586.</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>9. Nakazato M., Matsukura S. New Type of Amyloidosis b) Islet Amyloid Polypeptide (IAPP/Amylin) in Non-Insulin-Dependent Diabetes Mellitus. Internal Medicine. 1993; 32 (12): 928–929.</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>10. Gendlin G.E. Renal amyloidosis. Lechashchii vrach = Attending physician. 2000; 2: 8–10.</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>11. Brin V.B., Gabueva A.A., Kozyrev K.M. Effect of succinic acid and sulphide mineral water "Redant-4" separately and in combination on the functional-structural condition of the kidneys in the simulation of generalized amyloidosis neuropathic type. Kubanskii nauchnyi meditsinskii vestnik = Kuban research medical bulletin. 2010; 7 (121): 33–37.</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>12. Kisieva Z.A., Brin V.B., Kozyrev K.M. Influence mildronata and Acyzol on the basic processes of urine formation and excretion of electrolytes in Syrian golden hamsters with experimental model of amyloid nephropathy. Sovremennye problemy nauki i obrazovaniya = Modern problems of science and education. 2014; (2): 9. Available at: http://www.science-education.ru/pdf/2014/2/656.pdf (accessed: 27.01.2015).</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>13. Sjakste N., Baumane L., Boucher J.L., Dzintare M.,Meirena D., SjaksteJ., LauberteL., Kalvinsh I. Effects of gamma-butyrobetaine and mildronate on oxide production in lipopolysaccaride-treated rats. Basic Clin. Pharmacol. Toxicol. 2004; 94 (1): 46–50.</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>14. Forloni G., Angeretti N., Smiroldo S. Neuroprotective activity of acetyl-L-carnitine: studies in vitro. J. Neurosci. Res. 1994; 37 (1): 92–96.</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>15. Jang M.H., Piao X.L, Kim H.Y., Cho E.J., Baek S.H., Kwon S.W., Park J.H. Resveratrol oligomers from Vitisamurensis attenuate beta-amyloid-induced oxidative stress in PC12 cells. Biol. Pharm. Bull. 2007; 30: 1130–1134.</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>16. Savaskan E., Olivieri G., Meier F., Seifritz E., Wirz-Justice A., Muller-Spahn F. Red wine ingredient resveratrol protects from beta-amyloid neurotoxicity. Gerontology. 2003; 49: 380–383.</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>17. Kozlov V.A., Golenkov A.V., Sapozhnikov S.P. Effects of dry red wine and other alcoholic beverages on the development and course of Alzheimer's disease: the obvious, questionable and unknown. Psikhicheskoe zdorov'e = Mental health. 2014; 6 (97): C. 81–88.</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>18. Baza znanii po biologii cheloveka (Knowledge Base of Human Biology). Available at: http://humbio.ru/humbio/immunology/x003ee6f.htm (accessed: 27.01.2015).</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>19. Alam S., Suzuki H., Tsukahara T. Alternative splicing regulation of APP exon 7 by RBFox proteins. Neurochem. Int. 2014; pii: S0197-0186(14)00184-3. doi: 10.1016/j.neuint.2014.08.001.</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation>20. Goate A., Chartier-Harlin M.C., Mullan M., Brown G., Crawford F., Fidani L., Giuffra L., Haynes A., Irving N., James L., Mant R., Newton P., Rooke K., Rogues P., Talbot C., Pericak-Vance M., Roses A., Williamson R., Rossor M., Owen M., Hardy J. Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer’s disease. Nature. 1991; 349: 704–706.</mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation>21. Tanzi R., Gusella J., Watkins P., Bruns G.A., St George-Hyslop P., Van Keuren M.L., Patterson D., Pagan S., Kurnit D.M., Neve R.L. Amyloid beta-protein gene: cDNA, mRNA distribution and genetic linkage near the Alzheimer locus. Science. 1987; 235: 880–884.</mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation>22. Ando Y., Nakamura M., Araki S. Transthyretin-related family-alamyloidotic polyneuropathy. Arch. Neurol.2005; 62: 1057–1062.</mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation>23. Zhang C., Khandelwal P.J., Chakraborty R., Cuellar T.L., Sarangi S., Patel S.A., Cosentino C.P., O’Connor M., Lee J.C.,Tanzi R.E., Saunders A.J. An AICD-based functional screen to identify APP metabolism regulators. Mol. Neurodegener. 2007; 2 (15): 19 p. (page number not for citation purposes). DOI: 10.1186/1750-1326-2-15.</mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation>24. Lewis J., Dickson D.W., Lin Wen-Lang, Chisholm L., Corral A., Jones G., Yen Shu-Hui, Sahara N., Skipper L., Yager D., Eckman C., Hardy J., Hutton M., McGowan E. Enhanced Neurofibrillary Degeneration in Transgenic Mice Expressing Mutant Tau and APP. Science. 2001; 5534: 1487–1491.</mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation>25. Allen K.D., Chernova T.A., Tennant E.P., Wilkinson K.D., Chernoﬀ Y.O. Eﬀects of the ubiquitin system alterations on the de novo formation and loss of a yeast prion. J. Biol. Chem. 2007; 282: 3004–3013.</mixed-citation></ref><ref id="B26"><label>26.</label><mixed-citation>26. Bailleul P.A., Newnam G.P., Steenbergen J.N., Chernoﬀ Y.O. Genetic study of interactions between the cytoskeletal assembly protein Sla1 and prion-forming domain of the release factor Sup35 (eRF3) in Saccharomyces cerevisiae. Genetics. 1999; 153: 81–94.</mixed-citation></ref><ref id="B27"><label>27.</label><mixed-citation>27. Ganusova E.E., Ozolins L.N., Bhagat S., Newnam G.P., Wegrzyn R.D., Sherman M.Y., Chernoﬀ Y.O. Modulation of prion formation, aggregation and toxicity by the actin cytoskeleton in yeast. Mol. Cell. Biol. 2006; 26: 617–629.</mixed-citation></ref><ref id="B28"><label>28.</label><mixed-citation>28. Strittmatter W., Saunders A., Schmechel D., Pericak-Vance M., Enghild J., Salvesen G., Roses A. Apolipoprotein E: High avidity binding to b-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc. Natl. Acad. Sci. 1993; 90: 1977–1981.</mixed-citation></ref><ref id="B29"><label>29.</label><mixed-citation>29. Chernoﬀ Y.O. Protein heredity and evolution. In: Charles Darwin and Modern Biology: The Intern. Sci. Conference. E`.I. Kolchinskii`, A.A. Fedotova (eds). St. Petersburg: Nestor-Istoriia. 2010; 76–94.</mixed-citation></ref><ref id="B30"><label>30.</label><mixed-citation>30. Rivas A.L., Tintle L., Meyers-Wallen V., Scarlett J.M.,Van Tassell C., Quimby F.W. Inheritance of renal amyloidosis in Chi-nese Shar Pei dogs. J. Hered. 1993; 84 (6): 438–442.</mixed-citation></ref><ref id="B31"><label>31.</label><mixed-citation>31. Vidt J. SPAID — Shar-Pei Autoinflammatory Disorder [Элек-тронный ресурс]. http://drjwv.com/wp/2014/03/20/spaid-sharpei-autoinflammatory-disorder/ свободный (дата обращения: 27.01.2015).</mixed-citation></ref><ref id="B32"><label>32.</label><mixed-citation>32. Olsson M., Meadows J.R., Truvé K., Rosengren Pielberg G., Puppo F., Mauceli E., Quilez J., Tonomura N., Zanna G., Docampo M.J., Bassols A., Avery A.C., Karlsson E.K., Thomas A., Kastner D.L., Bongcam-Rudloff E., Webster M.T., Sanchez A., Hedhammar A., Remmers E.F., Andersson L., Ferrer L., Tintle L., Lindblad-Toh K. A novel unstable duplication upstream of HAS2 predisposes to a breed-defining skin phenotype and a periodicfever syndrome in Chinese Shar-Pei dogs. PLoS Genet. 2011; 7 (3): 1001332. DOI: 10.1371</mixed-citation></ref><ref id="B33"><label>33.</label><mixed-citation>33. Bowles M.H., Mosier D.A. Renal amyloidosis in a family of beagles. J. Am. Vet. Med. Assoc. 1992; 201 (4). P. 569–574.</mixed-citation></ref><ref id="B34"><label>34.</label><mixed-citation>34. Naumenko E.S. Spontannyi amiloidoz u nizshikh obez'yan: (patologicheskaya anatomiya, nekotorye voprosy patogeneza). Avtoref. dis. … kand. biol. nauk [Spontaneous Amyloidosis in the Lower Monkeys (Pathological Anatomy, some Questions of Pathogenesis). Author’s abstract]. Stavropol, 2004. 24 p.</mixed-citation></ref><ref id="B35"><label>35.</label><mixed-citation>35. Podlisny M.B., Tolan D.R., Selkoe D.J. Homology of the amyloid beta protein precursor in monkey and human supports a primate model for beta amyloidosis in Alzheimer’s disease. Am. J. Pathol. 1991; 138 (6): 1423–1435.</mixed-citation></ref><ref id="B36"><label>36.</label><mixed-citation>36. OakleyH., Cole S.L.,LoganS., Maus E., Shao P., CraftJ.,Guillozet-Bongaarts A., Ohno M., DisterhoftJ., Van EldikL., Berry R.,Vassar R. Intraneuronal beta-amyloidaggregates, neurodegeneration, and neuron loss in transgenic micewith the familial Alzheimer’s disease mutations: potential factors inamyloid plaque formation. J. Neuro-sci. 2006; 26 (40): 10129–10140.</mixed-citation></ref><ref id="B37"><label>37.</label><mixed-citation>37. Chew D.J., DiBartola S.P., Boyce J.T., GasperP.W. Renal amyloidosis in related Abyssinian cats. J. Am. Vet. Med. Assoc. 982; 181: 139–142.</mixed-citation></ref><ref id="B38"><label>38.</label><mixed-citation>38. Niewold T.A., van der Linde-Sipman J.S., Murphy C., TootenP.C., Gruys E. Familial amyloidosis in cats: Siamese and Abyssinian AA proteins differ in primary sequence and pattern of deposition. Amyloid. 1999; 6 (3): 205–209.</mixed-citation></ref><ref id="B39"><label>39.</label><mixed-citation>39. Littman M.P. Protein-losing Nephropathy in Small Animals. Vet. Clin. Small Anim. 2011; 41: 31–62. DOI:10.1016/j.cvsm.2010.09.006</mixed-citation></ref><ref id="B40"><label>40.</label><mixed-citation>40. Multhaup G., Schlicksupp A., Hesse L. The amyloidprecursor protein of Alzheimer`s disease in the reduction ofcopper (II) to copper (I). Science. 1996; 271: 1406–1409.</mixed-citation></ref><ref id="B41"><label>41.</label><mixed-citation>41. Xia W., Zhang J., Rezer R., Koo E. H., Selkoe D.J. Interaction between amyloid precursor protein and presenilins in mammalian cells: implications for the pathogenesis of Alzheimer disease. Proc. Natl. Acad. Sci. USA. 1997; 94 (15): 8208–8213.</mixed-citation></ref><ref id="B42"><label>42.</label><mixed-citation>42. Zhong Z., Hieaki J., Murakami K., Wang Y., Catalano R., Quon D., Cordell B. Secretion of beta-amyloid precursor protein involves multiple cleavage sites. J. Biol. Chem. 1994; 269: 627–632.</mixed-citation></ref><ref id="B43"><label>43.</label><mixed-citation>43. Qverfurth H.W., Jiang J., Geiger J.P. Caffeine stimulates amyloid beta-peptide release from beta-amyloid precursor protein-trans-fected HEK293 cells. J. Neurochem. 1997; 69 (4): 1580–1591.</mixed-citation></ref><ref id="B44"><label>44.</label><mixed-citation>44. Kapinus L.N. Immunomorphological study of the early stages of amyloidogenesis. Bull. Exp. Biol. Med.(Russia). 1978; 85 (2): 232–234.</mixed-citation></ref><ref id="B45"><label>45.</label><mixed-citation>45. Domagk G. Untersuchungenuber die Bedeutung des reticuloendothelial systems fur die Entstehung d. Amyloids, Virchows Archiv. B. CCLIII. 1924; 253: 594–638.</mixed-citation></ref><ref id="B46"><label>46.</label><mixed-citation>46. Cui D., Kawano H., Takahashi M. Hoshii Y., Setoguchi M., Gon-do T., Ishihara T. Acceleration of murine AA amyloidosis by oral administration of amyloid fibrils extracted from different species. Pathol. Int. 2002; 52 (1): 40–45.</mixed-citation></ref><ref id="B47"><label>47.</label><mixed-citation>47. Kennedy J.S., Anderson J.D. The effect of treatment of the associated disease on the development of amyloidosis in the experimental animal. J. Pathol. 1983; 141 (1): 11–15.</mixed-citation></ref><ref id="B48"><label>48.</label><mixed-citation>48. ГGritsman A.Yu. Nekotorye voprosy eksperimental'noi terapii amiloidoza i rezorbtsii amiloida. Avtoref. dis. ... kand. med. nauk [Some Questions Experimental Therapeutics Amyloidosis and Amyloid Resorption. Author’s abstract]. Moscow, 1974. 24 p.</mixed-citation></ref><ref id="B49"><label>49.</label><mixed-citation>49. Zaalishvili T.V., Kozy`rev K.M. Methods simulation of amyloidosis in experimental animals. Adv. Curr. Nat. Sci. (Russia). 2005; 2: 78–79.</mixed-citation></ref><ref id="B50"><label>50.</label><mixed-citation>50. Pat. 2269825 Russian Federation (51) IPC G09B23/28 the Way of modeling of experimental amyloidosis in animals. Zaalishvili T.V., Kozyrev K.M. applicants and patent holder of the State Educational Institution of Higher Professional Education North-Ossetian State Medical Academy of the Federal Agency for Healthcare and Social Development of the Russian Federation. No. 2004127649/14, Appl. 15.09.2004; Publ. 10.02.2006. Bull. № 11. 7 p.</mixed-citation></ref><ref id="B51"><label>51.</label><mixed-citation>51. Kravkov N.P. Ob amiloide, eksperimental'no vyzyvaemom u zhivotnykh. Dis. … dokt. med. nauk [On Amyloid Experimentally Causes in Animals. Author’s abstract]. St. Petersburg, 1894. 46 p.</mixed-citation></ref><ref id="B52"><label>52.</label><mixed-citation>52. Pat. 2373581 Russian Federation (51) IPC G09B23/28 Method modeling of experimental amyloidosis in animals. Gabueva A.A., Kozyrev K.M., Brin V.B. applicants and patent holder of the State Educational Institution of Higher Professional Education North-Ossetian State Medical Academy of the Federal Agency for Healthcare and Social Development of the Russian Federation. No. 2008128201/14, Appl. 10.07.2008; Publ. 20.11.2009. Bull. № 32. 8 p.</mixed-citation></ref><ref id="B53"><label>53.</label><mixed-citation>53. Sokolovskiy N.V. Functionally and morphological characteristics of the experimental prophilactic of cardiac amyloidosis rats acizol and succinic acid. Modern Probl. Sci Ed. 2014; 1: 19. http://www. science-education.ru/pdf/2014/1/450.pdf (available: 27.01.2015).</mixed-citation></ref><ref id="B54"><label>54.</label><mixed-citation>54. Pat. 2347279 Russian Federation (51) IPC G09B23/28 the Way of modeling of experimental amyloidosis in animals. Puhova I.U., Brin V.B., Kozyrev C.M. applicants and patent holder of the State Educational Institution of Higher Professional Education North-Ossetian State Medical Academy of the Federal Agency for Healthcare and Social Development of the Russian Federation. No. 2007135901/14, Appl. 27.09.2007; Publ. 20.02.2009. Bull. № 6. 7 p.</mixed-citation></ref><ref id="B55"><label>55.</label><mixed-citation>55. Pat. 2473133 Russian Federation (51) IPC G09B 23/28; A61K 31/502; A61P 13/12 Method of prevention of systemic amyloidosis and its renal forms in experimental animals. Brin V.B., Belikova A.T., Kozyrev K.M. applicants and patent holder of the State Educational Institution of Higher Professional Education North-Ossetian State Medical Academy of the Federal Agency for Healthcare and Social Development of the Russian Federation. No. 2011112243/14, Appl. 30.03.2011; Publ. 20.01.2013. Bull. № 2. 10 p.</mixed-citation></ref><ref id="B56"><label>56.</label><mixed-citation>56. Pat. 2270672 Russian Federation (51) IPC A61K 31/15; A61P 13/12 Method of prevention and treatment of systemic amyloidosis and its renal forms in experimental animals. Zaalishvili T.V., Kozyrev K.M. applicants and patent holder of the State Educational Institution of Higher Professional Education North-Ossetian State Medical Academy of the Federal Agency for Healthcare and Social Development of the Russian Federation. No. 2004127648/14, Appl. 15.09.2004; Publ. 27.02.2006. Bull. № 6. 7 p.</mixed-citation></ref><ref id="B57"><label>57.</label><mixed-citation>57. Pat. 2306617 Russian Federation (51) МПКG09B23/28 the Way of modeling of experimental amyloidosis in animals. Kozyrev K.M., Zaalishvili T.V., Brin V.B., Gioeva Z.V. applicants and patent holder of the State Educational Institution of Higher Professional Education North-Ossetian State Medical Academy of the Federal Agency for Healthcare and Social Development of the Russian Federation. No. 2006113109/13, Appl. 18.04.2006; Publ. 20.09.2007. Bull. № 36. 8 p.</mixed-citation></ref><ref id="B58"><label>58.</label><mixed-citation>58. Pat. 2446482 Russian Federation (51) IPC G09В23/28 the Way of modeling of experimental amyloidosis in animals. Brin V.B., Belikova A.T., Kozyrev K.M. applicants and patent owner of the State Educational Institution of Higher Professional Education North-Ossetian State Medical Academy of the Federal Agency for Healthcare and Social Development of the Russian Federation. No. 2010146365/14, Appl. 13.11.2010; Publ. 27.03.2012. Bull. № 9. 9 p.</mixed-citation></ref><ref id="B59"><label>59.</label><mixed-citation>59. Pat. 2473134 Russian Federation (51) IPC G09В23/28 Method of prevention of systemic amyloidosis and its renal forms in experimental animals. Belikova A.T., Brin V.B., Kozyrev K.M. applicants and patent owner of the State Educational Institution of Higher Professional Education North-Ossetian State Medical Academy of the Federal Agency for Healthcare and Social Development of the Russian Federation. No. 2011111891/14, Appl. 29.03.2011; Publ. 20.01.2013. Bull. № 2. 9 p.</mixed-citation></ref><ref id="B60"><label>60.</label><mixed-citation>60. Akamatsu Y., Ikegami R. Induction of hepatoma and systemic amyloidosis in mice by 4-(dimethylamino) azobenzene feeding. Gann. 1968; 59 (3): 201–206.</mixed-citation></ref><ref id="B61"><label>61.</label><mixed-citation>61. Shvarts S.S. Ekologicheskie zakonomernosti evolyutsii [Environmental Laws of Evolution]. Moscow, Nauka, 1980. 153 p.</mixed-citation></ref><ref id="B62"><label>62.</label><mixed-citation>62. Stefani M., Dobson C.M. Protein aggregation and aggregate toxicity: new insights into protein folding, misfolding diseases and biological evolution. J. Mol. Med. 2003; 81: 678–699.</mixed-citation></ref><ref id="B63"><label>63.</label><mixed-citation>63. Sapozhnikov S. P. Role of silicon compounds in the development of autoimmune processes. Trace Elements in Medicine (Russia). 2013; 3: 3–13.</mixed-citation></ref><ref id="B64"><label>64.</label><mixed-citation>64. Lansbury P.T., Jr., Caughey B. The chemistry of scrapie infection: implications of the ‘ice 9′ metaphor. Chemistry &amp; Biology. 1995; 2: 1–5.</mixed-citation></ref><ref id="B65"><label>65.</label><mixed-citation>65. Kim J.I., Cali I., Surewicz K., Kong Q., Raymond G.J., Atarashi R., Race B., Qing L., Gambetti P., Caughey B., Surewicz W.K. Mammalian prions generated from bacterially expressed prion protein in the absence of any mammalian cofactors. J. Biol. Chem. 2010; 285: 14083–14087.</mixed-citation></ref><ref id="B66"><label>66.</label><mixed-citation>66. Wang F., Wang X., Yuan C.G., Ma J. Generating a prion with bacterially expressed recombinant prion protein. Science. 2010; 327: 1132–1135.</mixed-citation></ref><ref id="B67"><label>67.</label><mixed-citation>67. Teilum G. Studies on pathogeneiss of amyloidosis; effect of nitrogen mustard in inducing amyloidosis. J. Lab. Clin. Med. 1954; 43: 367.</mixed-citation></ref><ref id="B68"><label>68.</label><mixed-citation>68. Letterer E. Studienuber Art und Enstehung des Amyloids. Beitr. Path. Anat. 1926; 75: 486–588.</mixed-citation></ref><ref id="B69"><label>69.</label><mixed-citation>69. Loeschke H. Vorstellungenuber das Wesen von Hyalin und amlyoid auf Grund von serologische. Versuchen. Beitr. path. Anat. 1927; 77: 231–239.</mixed-citation></ref><ref id="B70"><label>70.</label><mixed-citation>70. Cagli V. La amiloidosi. Policlinico. Sez. prat. 1961; 68 (49): 1801– 1814.</mixed-citation></ref></ref-list></back></article>
